You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,357,714


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,357,714 protect, and when does it expire?

Patent 8,357,714 protects UPNEEQ and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 8,357,714
Title:Compositions and methods for non-surgical treatment of ptosis
Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Inventor(s): Silverberg; Mark (Santa Barbara, CA)
Assignee: Voom, LLC (Santa Barbara, CA)
Application Number:13/270,577
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,357,714

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial METHOD OF TREATING BLEPHAROPTOSIS ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,357,714

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012223615 ⤷  Try a Trial
Brazil 112013022094 ⤷  Try a Trial
Canada 2827285 ⤷  Try a Trial
China 103501771 ⤷  Try a Trial
Cyprus 1122565 ⤷  Try a Trial
Denmark 2680829 ⤷  Try a Trial
European Patent Office 2680829 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.